KRT18 and COVID-19: They also demonstrated that bromodomain and extra-terminal family (BET) inhibition was a promising therapeutic candidate to prevent COVID-19-induced heart damage, as BET inhibitors recovered dysfunction in cardiac organoids treated with the cytokine storm or COVID-19 patient-derived serum, and rescued cardiac dysfunction and death in SARS-CoV-2-infected K18-hACE2 mice.